Trial
NCT04045730
The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Yale University
Collaborators
—
Condition
Pancreas Adenocarcinoma
Intervention
Gemcitabine
Why stopped
Halozyme isn't allowing this trial to move forward until their current clinical trial results are released.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-09